Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects
Status:
Unknown status
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
This is a 48-week study to evaluate the safety, tolerability, pharmacokinetics, and antiviral
activity of an investigational regimen including FDA approved HIV drugs in HIV-infected
pediatric subjects, ages 4 weeks to < 2 years old.
Phase:
Phase 2
Details
Lead Sponsor:
ViiV Healthcare
Collaborator:
GlaxoSmithKline
Treatments:
Fosamprenavir HIV Protease Inhibitors Protease Inhibitors Ritonavir